Topotecan for the treatment of relapsed small-cell lung cancer

TA184 Lung cancer (small-cell) - topotecan: review decision - February 2013  information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 101 KB)

TA184 Lung cancer (small-cell) - topotecan: review proposal - November 2012 information

Appendix A: provisional matrix of stakeholders (PDF 59 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 160 KB)

Lung cancer (small-cell, second line treatment) - topotecan: final appraisal determination information

Lung cancer (small-cell, second line treatment) - topotecan: final appraisal determination (PDF 125 KB)

Response to consultee, commentator and public comments on the ACD (PDF 33 KB)

Consultee and commentator comments on the appraisal consultation document

NHS Quality Improvement Scotland comment on ACD (PDF 9.5 KB)

Welsh Assembly Government comment on ACD (PDF 12 KB)

Department of Health comment on ACD (PDF 19 KB)

Roy Castle Lung Cancer Foundation comment on ACD (PDF 39 KB)

Royal College of Nursing comment on ACD (PDF 22 KB)

Manufacturer comment on ACD (PDF 14 KB)

Expert comment from Allan Price (PDF 19 KB)

Lung cancer (small-cell, second line treatment) - topotecan: appraisal consultation information

Lung cancer (small-cell, second line treatment) - topotecan : appraisal consultation document information

Lung cancer (small-cell, second line treatment) - topotecan: evaluation report

Lung cancer (small-cell, second line treatment) - topotecan: overview (PDF 141 KB)

Lung cancer (small-cell, second line treatment) - topotecan: assessment report (PDF 1.47 MB)

Lung cancer (small-cell, second line treatment) - topotecan: Consultee and commentator comments on the assessment report

Lung cancer (small-cell, second line treatment) - topotecan: Consultee and commentator comments on the assessment report - NHS Quality Improvement Scotland (PDF 18 KB)

Lung cancer (small-cell, second line treatment) - topotecan: Consultee and commentator comments on the assessment report - GlaxoSmithKline (PDF 63 KB)

Lung cancer (small-cell, second line treatment) - topotecan: Consultee and commentator comments on the assessment report - Professor Allan Price (PDF 12 KB)

Lung cancer (small-cell, second line treatment) - topotecan: Consultee and commentator comments on the assessment report - Royal College of Nursing (PDF 18 KB)

Lung cancer (small-cell, second line treatment) - topotecan: Assessment Group response to manufacturer comments on the Assessment Report (PDF 13 KB)

Lung cancer (small-cell, second line treatment) - topotecan: Non-manufacturer submissions

Lung cancer (small-cell, second line treatment) - topotecan: Non-manufacturer submissions - Roy Castle Lung Cancer Foundation (PDF 40 KB)

Lung cancer (small-cell, second line treatment) - topotecan: Non-manufacturer submissions - Royal College of Nursing (PDF 22 KB)

Lung cancer (small-cell, second line treatment) - topotecan: Non-manufacturer submissions - NCRI, RCP, RCR, ACP, JCCO (PDF 8.3 KB)

Lung cancer (small-cell, second line treatment) - topotecan: Manufacturer submissions - GlaxoSmithKline (PDF 83 KB)

Lung cancer (small-cell, second line treatment) - topotecan: Expert written personal statements - Braybrooke (PDF 16 KB)

Lung cancer (small-cell, second line treatment) - topotecan: Final Protocol (PDF 168 KB)

Lung cancer (small-cell, second line treatment) - topotecan: final scope (PDF 31 KB)

Lung cancer (small-cell, second line treatment) - topotecan: response to consultee and commentator comments on the draft scope (PDF 57 KB)

Lung cancer (small-cell, second line treatment) - topotecan: response to consultee and commentator comments on the provisional matrix (PDF 21 KB)